Search

Your search keyword '"Ghadimi, Michael"' showing total 823 results
Start Over Author "Ghadimi, Michael" Publication Year Range Last 50 years
823 results on '"Ghadimi, Michael"'

3. Transatlantic differences in the use and outcome of minimally invasive pancreatoduodenectomy: an international multi-registry analysis

Author

de Graaf, Nine, Augustinus, Simone, Wellner, Ulrich F., Johansen, Karin, Andersson, Bodil, Beane, Joal D., Björnsson, Bergthor, Busch, Olivier R., Davis, Catherine H., Ghadimi, Michael, Gleeson, Elizabeth M., Groot Koerkamp, Bas, Hogg, Melissa E., van Santvoort, Hjalmar C., Tingstedt, Bobby, Uhl, Waldemar, Werner, Jens, Williamsson, Caroline, Zeh, Herbert J., Zureikat, Amer H., Abu Hilal, Mohammad, Pitt, Henry A., Besselink, Marc G., and Keck, Tobias

Published
2024
Full Text
View/download PDF

10. Consensus Statement on the Use of Near-Infrared Fluorescence Imaging during Pancreatic Cancer Surgery Based on a Delphi Study: Surgeons’ Perspectives on Current Use and Future Recommendations

Author

de Muynck, Lysanne DAN, White, Kevin P, Alseidi, Adnan, Bannone, Elisa, Boni, Luigi, Bouvet, Michael, Falconi, Massimo, Fuchs, Hans F, Ghadimi, Michael, Gockel, Ines, Hackert, Thilo, Ishizawa, Takeaki, Kang, Chang Moo, Kokudo, Norihiro, Nickel, Felix, Partelli, Stefano, Rangelova, Elena, Swijnenburg, Rutger Jan, Dip, Fernando, Rosenthal, Raul J, Vahrmeijer, Alexander L, and Mieog, J Sven D

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Pancreatic Cancer, Rare Diseases, Cancer, Digestive Diseases, fluorescence-guided surgery, intraoperative imaging, pancreatic cancer, cancer surgery, near-infrared fluorescence, indocyanine green, consensus, Delphi, Oncology and carcinogenesis
Abstract

Indocyanine green (ICG) is one of the only clinically approved near-infrared (NIR) fluorophores used during fluorescence-guided surgery (FGS), but it lacks tumor specificity for pancreatic ductal adenocarcinoma (PDAC). Several tumor-targeted fluorescent probes have been evaluated in PDAC patients, yet no uniformity or consensus exists among the surgical community on the current and future needs of FGS during PDAC surgery. In this first-published consensus report on FGS for PDAC, expert opinions were gathered on current use and future recommendations from surgeons' perspectives. A Delphi survey was conducted among international FGS experts via Google Forms. Experts were asked to anonymously vote on 76 statements, with ≥70% agreement considered consensus and ≥80% participation/statement considered vote robustness. Consensus was reached for 61/76 statements. All statements were considered robust. All experts agreed that FGS is safe with few drawbacks during PDAC surgery, but that it should not yet be implemented routinely for tumor identification due to a lack of PDAC-specific NIR tracers and insufficient evidence proving FGS's benefit over standard methods. However, aside from tumor imaging, surgeons suggest they would benefit from visualizing vasculature and surrounding anatomy with ICG during PDAC surgery. Future research could also benefit from identifying neuroendocrine tumors. More research focusing on standardization and combining tumor identification and vital-structure imaging would greatly improve FGS's use during PDAC surgery.

Published
2023

11. International differences in the selection and outcome of minimally invasive and open distal pancreatectomy: A transatlantic analysis

Author

Johansen, Karin U., Augustinus, Simone, Wellner, Ulrich F., Andersson, Bodil, Beane, Joal D., Björnsson, Bergthor, Busch, Olivier R., Davis, Catherine H., Ghadimi, Michael, Gleeson, Elizabeth M., de Graaf, Nine, Koerkamp, Bas Groot, Pitt, Henry A., van Santvoort, Hjalmar C., Tingstedt, Bobby, Uhl, Waldemar, Werner, Jens, Williamsson, Caroline, Besselink, Marc G., and Keck, Tobias

Published
2024
Full Text
View/download PDF

12. Chemoradiotherapy plus induction or consolidation chemotherapy as total neoadjuvant therapy for locally advanced rectal cancer: Pooled analysis of the CAO/ARO/AIO-12 and the OPRA randomized phase 2 trials

Author

Fokas, Emmanouil, Williams, Hannah, Diefenhardt, Markus, Lin, Sabrina, Qin, Li-Xuan, Piso, Pompiliu, Dapper, Hendrik, Germer, Christoph-Thomas, Grützmann, Robert, Tim Friede, J., Joshua Smith, J., Saltz, Leonard B., Wu, Abraham J., Weiser, Martin R., Omer, Dana, Ghadimi, Michael, Hofheinz, Ralf-Dieter, Garcia-Aguilar, Julio, and Rödel, Claus

Published
2024
Full Text
View/download PDF

13. High CIB1 expression in colorectal cancer liver metastases correlates with worse survival and the replacement histopathological growth pattern

Author

Fan, Shuang, Fleischer, Johannes Robert, Dokshokova, Lolita, Böhme, Lena Sophie, Haas, Gwendolyn, Schmitt, Alexandra Maria, Gätje, Fabio Bennet, Rosen, Linde-Allegra Emmalie, Bohnenberger, Hanibal, Ghadimi, Michael, Cui, Baolong, Xu, Xingbo, Kalucka, Joanna Maria, Bösch, Florian, De Oliveira, Tiago, and Conradi, Lena-Christin

Published
2024
Full Text
View/download PDF

18. Safety and performance of a synthetic sealant patch aimed to prevent postoperative pancreatic fistula after distal pancreatectomy (SHIELDS) – Prospective international multicenter phase II study

Author

Goetz, Mara R., Heumann, Asmus, Bassi, Claudio, Landoni, Luca, Khatib-Chahidi, Karl, Ghadimi, Michael, von Heessen, Maximillian, Berrevoet, Frederik, Gryspeerdt, Filip, Besselink, Marc, van Bodegraven, Eduard A., Adham, Mustapha, Pratschke, Johann, Schöning, Wenzel, Izbicki, Jakob R., and Bockhorn, Maximilian

Published
2024
Full Text
View/download PDF

21. Molecular differences of angiogenic versus vessel co-opting colorectal cancer liver metastases at single-cell resolution

Author

Fleischer, Johannes Robert, Schmitt, Alexandra Maria, Haas, Gwendolyn, Xu, Xingbo, Zeisberg, Elisabeth Maria, Bohnenberger, Hanibal, Küffer, Stefan, Teuwen, Laure-Anne, Karras, Philipp Johannes, Beißbarth, Tim, Bleckmann, Annalen, Planque, Mélanie, Fendt, Sarah-Maria, Vermeulen, Peter, Ghadimi, Michael, Kalucka, Joanna, De Oliveira, Tiago, and Conradi, Lena-Christin

Published
2023
Full Text
View/download PDF

30. Clinical outcome after total neoadjuvant treatment (CAO/ARO/AIO-12) versus intensified neoadjuvant and adjuvant treatment (CAO/ARO/AIO-04) a comparison between two multicenter randomized phase II/III trials

Author

Diefenhardt, Markus, Fleischmann, Maximillian, Martin, Daniel, Hofheinz, Ralf-Dieter, Piso, Pompiliu, Germer, Christoph-Thomas, Hambsch, Peter, Grützmann, Robert, Kirste, Simon, Schlenska-Lange, Anke, Ghadimi, Michael, Rödel, Claus, and Fokas, Emmanouil

Published
2023
Full Text
View/download PDF

33. Prospective randomized multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (ESOPEC trial).

Author

Hoeppner, Jens, primary, Brunner, Thomas, additional, Lordick, Florian, additional, Schmoor, Claudia, additional, Kulemann, Birte, additional, Neumann, Ulf Peter, additional, Folprecht, Gunnar, additional, Keck, Tobias, additional, Benedix, Frank, additional, Schmeding, Maximilan, additional, Reitsamer, Ernst, additional, Bruns, Christiane J., additional, Lock, Johan F., additional, Reichert, Benedikt, additional, Ghadimi, Michael, additional, Wille, Kai, additional, Gockel, Ines, additional, Izbicki, Jakob R., additional, Utzolino, Stefan, additional, and Grimminger, Peter Philipp, additional

Published
2024
Full Text
View/download PDF

34. Perioperative outcomes in an age-adapted analysis of the German StuDoQ|Pancreas registry for PDAC

Author

Tschaidse, Tengis, primary, Hofmann, Felix O., additional, Renz, Bernhard, additional, Hungbauer, Maximilian, additional, Klinger, Carsten, additional, Buhr, Heinz J, additional, Uhl, Waldemar, additional, Mees, Sören Torge, additional, Reissfelder, Christoph, additional, Ghadimi, Michael, additional, D'Haese, Jan G., additional, Werner, Jens, additional, Ilmer, Matthias, additional, and Keck, Tobias, additional

Published
2024
Full Text
View/download PDF

40. Arbeitsgruppen zu kolorektalen Tumoren der AIO, der ACO und der ARO – „past, present, and future“

Author

Hofheinz, Ralf, Arnold, Dirk, Fichtner-Feigl, Stefan, Fokas, Emmanouil, Folprecht, Gunnar, Geissler, Michael, Ghadimi, Michael, Hegewisch-Becker, Susanne, Heinemann, Volker, Kasper-Virchow, Stefan, Kubicka, Stefan, Modest, Dominik Paul, Piso, Pompilio, Reinacher-Schick, Anke, Rödel, Claus-Michael, Seufferlein, Thomas, Stein, Alexander, and Stintzing, Sebastian

Published
2022
Full Text
View/download PDF

46. MIF/NR3C2 axis regulates glucose metabolism reprogramming in pancreatic cancer through MAPK–ERK and AP-1 pathways.

Author

Yang, Shouhui, Tang, Wei, Azizian, Azadeh, Gaedcke, Jochen, Ohara, Yuuki, Cawley, Helen, Hanna, Nader, Ghadimi, Michael, Lal, Trisha, Sen, Subrata, Creighton, Chad J, Gao, Jianjun, Putluri, Nagireddy, Ambs, Stefan, and Hussain, Perwez

Subjects
MACROPHAGE migration inhibitory factor, METABOLIC reprogramming, AP-1 transcription factor, METABOLIC regulation, INFLAMMATORY mediators, LACTATES, PROTEIN kinases
Abstract

Inflammation and aberrant cellular metabolism are widely recognized as hallmarks of cancer. In pancreatic ductal adenocarcinoma (PDAC), inflammatory signaling and metabolic reprogramming are tightly interwoven, playing pivotal roles in the pathogenesis and progression of the disease. However, the regulatory functions of inflammatory mediators in metabolic reprogramming in pancreatic cancer have not been fully explored. Earlier, we demonstrated that pro-inflammatory mediator macrophage migration inhibitory factor (MIF) enhances disease progression by inhibiting its downstream transcriptional factor nuclear receptor subfamily 3 group C member 2 (NR3C2). Here, we provide evidence that MIF and NR3C2 interactively regulate metabolic reprogramming, resulting in MIF-induced cancer growth and progression in PDAC. MIF positively correlates with the HK1 (hexokinase 1), HK2 (hexokinase 2) and LDHA (lactate dehydrogenase) expression and increased pyruvate and lactate production in PDAC patients. Additionally, MIF augments glucose uptake and lactate efflux by upregulating HK1, HK2 and LDHA expression in pancreatic cancer cells in vitro and in mouse models of PDAC. Conversely, a reduction in HK1, HK2 and LDHA expression is observed in tumors with high NR3C2 expression in PDAC patients. NR3C2 suppresses HK1, HK2 and LDHA expression, thereby inhibiting glucose uptake and lactate efflux in pancreatic cancer. Mechanistically, MIF-mediated regulation of glycolytic metabolism involves the activation of the mitogen-activated protein kinase–ERK signaling pathway, whereas NR3C2 interacts with the activator protein 1 to regulate glycolysis. Our findings reveal an interactive role of the MIF/NR3C2 axis in regulating glucose metabolism supporting tumor growth and progression and may be a potential target for designing novel approaches for improving disease outcome. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

47. ELAPOR1 induces the classical/progenitor subtype and contributes to reduced disease aggressiveness through metabolic reprogramming in pancreatic cancer.

Author

Ohara, Yuuki, Liu, Huaitian, Craig, Amanda J., Yang, Shouhui, Moreno, Paloma, Dorsey, Tiffany H., Cawley, Helen, Azizian, Azadeh, Gaedcke, Jochen, Ghadimi, Michael, Hanna, Nader, Ambs, Stefan, and Hussain, S. Perwez

Subjects
METABOLIC reprogramming, PANCREATIC cancer, TRANSGENE expression, AMINO acid metabolism, GENE expression
Abstract

Pancreatic ductal adenocarcinoma (PDAC) is a heterogeneous disease with distinct molecular subtypes described as classical/progenitor and basal‐like/squamous PDAC. We hypothesized that integrative transcriptome and metabolome approaches can identify candidate genes whose inactivation contributes to the development of the aggressive basal‐like/squamous subtype. Using our integrated approach, we identified endosome–lysosome associated apoptosis and autophagy regulator 1 (ELAPOR1/KIAA1324) as a candidate tumor suppressor in both our NCI‐UMD‐German cohort and additional validation cohorts. Diminished ELAPOR1 expression was linked to high histological grade, advanced disease stage, the basal‐like/squamous subtype, and reduced patient survival in PDAC. In vitro experiments demonstrated that ELAPOR1 transgene expression not only inhibited the migration and invasion of PDAC cells but also induced gene expression characteristics associated with the classical/progenitor subtype. Metabolome analysis of patient tumors and PDAC cells revealed a metabolic program associated with both upregulated ELAPOR1 and the classical/progenitor subtype, encompassing upregulated lipogenesis and downregulated amino acid metabolism. 1‐Methylnicotinamide, a known oncometabolite derived from S‐adenosylmethionine, was inversely associated with ELAPOR1 expression and promoted migration and invasion of PDAC cells in vitro. Taken together, our data suggest that enhanced ELAPOR1 expression promotes transcriptome and metabolome characteristics that are indicative of the classical/progenitor subtype, whereas its reduction associates with basal‐like/squamous tumors with increased disease aggressiveness in PDAC patients. These findings position ELAPOR1 as a promising candidate for diagnostic and therapeutic targeting in PDAC. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

49. Individualisierte Pankreaschirurgie

Author

Bruns, Christiane, Popp, Felix, Friess, Helmut, Hüser, Norbert, Aßfalg, Volker, Hartmann, Daniel, Grützmann, Robert, Brunner, Maximillian, Weber, Georg, Werner, Jens, D’Haese, Jan G., Ghadimi, Michael, Gaedcke, Jochen, Izbicki, Jakob, Heumann, Asmus, Boggi, Ugo, Menonna, Francesca, Iacopi, Sara, Amorese, Gabriella, Giulianotti, Pier Cristoforo, Cornejo, Gabriela Aguiluz, Bustos, Roberto, Bianco, Francesco, Keck, Tobias, Weitz, Jürgen, Teske, Christian, Welsch, Thilo, Korenkov, Michael, editor, Germer, Christoph-Thomas, editor, and Lang, Hauke, editor

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results